INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
Search

All disclosures

Every ingested record across SEC Form 4, 13F, House PTRs and Robinhood Chain, searchable by ticker, name or wallet address.

Results

Data sources
SEC Form 42h ago
House PTR2h ago
SEC 13F2h ago
Robinhood Chain2h ago

Results

20,939 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
25
MD
Moore Alexander D.Director
PLTRPalantir Technologies Inc.
Open-market sale · 10b5-1 plan
SELL$1.38M
9,212 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

Page 390 of 524
← PrevNext →
23
FA
Fang AndyDirector
DASHDoorDash, Inc.
Open-market sale · 10b5-1 plan
SELL
$8,162
40 sh
Feb 2, 2026
Feb 4, 2026
traded Feb 2, 2026
+2d
SEC Form 4

Evidence

23
FA
Fang AndyDirector
DASHDoorDash, Inc.
Open-market sale · 10b5-1 plan
SELL$16K
80 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

23
SF
Stat Lauren Elaina FriedmanDirector
PLTRPalantir Technologies Inc.
Open-market sale · 10b5-1 plan
SELL$60K
400 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

23
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$4,723
100 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

23
FA
Fang AndyDirector
DASHDoorDash, Inc.
Open-market sale · 10b5-1 plan
SELL$41K
200 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

22
FJ
Fesko JohnPRESIDENT, CHIEF BUS. OFFICER
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$558K
2,415 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

22
MD
Moore Alexander D.Director
PLTRPalantir Technologies Inc.
Open-market sale · 10b5-1 plan
SELL$374K
2,525 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

22
MD
Moore Alexander D.Director
PLTRPalantir Technologies Inc.
Open-market sale · 10b5-1 plan
SELL$942K
6,310 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

22
SA
Smith Michael AlexanderChief Legal Officer
INSMINSMED Inc
Open-market sale
SELL$100K
640 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

22
RD
Rabinowitz DanielSEC. AND CHIEF LEGAL OFFICER
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$308K
1,334 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

22
FJ
Fesko JohnPRESIDENT, CHIEF BUS. OFFICER
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$272K
1,179 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

21
MI
Mat IshbiaDirector, President and CEO, 10% Owner
UWMCUWM Holdings Corp
Open-market sale · 10b5-1 plan
SELL$3.30M
632.9K sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

21
MI
Mat IshbiaDirector, President and CEO, 10% Owner
UWMCUWM Holdings Corp
Open-market sale · 10b5-1 plan
SELL$3.20M
632.9K sh
Feb 4, 2026Feb 4, 2026
traded Feb 4, 2026
+0dSEC Form 4

Evidence

20
ST
Schwartz Richard ToddDirector, Chief Executive Officer
RSIRush Street Interactive, Inc.
Open-market sale · 10b5-1 plan
SELL$4.35M
247.1K sh
Feb 4, 2026Feb 4, 2026
traded Feb 4, 2026
+0dSEC Form 4

Evidence

20
MC
Malenka Robert C.Director
MPLTMapLight Therapeutics, Inc.
Open-market sale
SELL$127K
7,039 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

19
MD
Moore Alexander D.Director
PLTRPalantir Technologies Inc.
Open-market sale · 10b5-1 plan
SELL$106K
720 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

19
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$187K
4,064 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

19
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$378K
1,639 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

19
MD
Moore Alexander D.Director
PLTRPalantir Technologies Inc.
Open-market sale · 10b5-1 plan
SELL$186K
1,233 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

18
HC
Howse CurtisSee remarks
SYFSynchrony Financial
Open-market sale · 10b5-1 plan
SELL$3.80M
52.6K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

17
MC
Malabre Richard CSVP, Chief Accounting Officer
AKBAAkebia Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$50K
36.1K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

17
MC
Malenka Robert C.Director
MPLTMapLight Therapeutics, Inc.
Open-market sale
SELL$18
1 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

16
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$133K
576 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

16
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$197K
850 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

16
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$140K
600 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

16
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$202K
878 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

16
SM
Stetz MattiasChief Operating Officer
RSIRush Street Interactive, Inc.
Open-market sale · 10b5-1 plan
SELL$353K
20.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

13
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$3,744
16 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

13
WS
Wampler Kira SchererDirector
DOCSDoximity, Inc.
Open-market sale · 10b5-1 plan
SELL$75K
2,000 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

13
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$18K
80 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

13
SJ
Schafer JoshuaCCO
ZVRAZEVRA THERAPEUTICS, INC.
Open-market sale · 10b5-1 plan
SELL$97K
10.5K sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

13
SM
Sharma ManishChief Strategy & Services Ofcr
ACNAccenture plc
Open-market sale · 10b5-1 plan
SELL$25K
98 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

12
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$34K
736 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

11
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$27K
600 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

11
HK
Holleran KevinDirector, President and CEO
HAYWHayward Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$841K
52.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

10
RM
Rucci Carolyn M.SVP, Chief Legal Officer
AKBAAkebia Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$35K
25.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

10
AL
Alpern Paul LVP and General Counsel
AIPArteris, Inc.
Open-market sale · 10b5-1 plan
SELL$77K
5,000 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

10
MC
Malabre Richard CSVP, Chief Accounting Officer
AKBAAkebia Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$19K
13.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

10
RM
Rucci Carolyn M.SVP, Chief Legal Officer
AKBAAkebia Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$23K
16.8K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence